Airway Therapeutics Closes $50 Million Equity Round to Advance Late-Stage Development of Zelpultide Alfa

Summary

Airway Therapeutics closed a $50 million Series E-2 equity round with approximately 94% participation from existing investors to support late-stage development of Zelpultide Alfa for prevention of bronchopulmonary dysplasia. The funding will advance the ongoing Phase 2b/3 clinical trial and related CMC and analytical activities.